TipHub

₹580

▲ +0.29 +0.05%

As of 27 Jul 2026 · delayed

NSE Listed

ENCUMBRANCE
What does ENCUMBRANCE mean?
BSE · High Promoter / Non-promoter EncumbranceA large share of the stock is pledged as loan collateral. Practical meaning: a falling price can trigger lenders to invoke pledges and dump shares — a self-reinforcing crash risk — and promoter pledging signals owner-level balance-sheet stress beyond the company's own books.Criteria: High level of encumbered (pledged) shares held by promoter and non-promoter entities, flagged under SEBI (Substantial Acquisition of Shares & Takeovers) Regulation 28(3).Exchange notice · 2026-05-12

Thyrocare Technologies Ltd. (THYROCARE)

Volume: 39,58,272Avg Vol 1W: 34,91,224.2Avg Vol 1M: 11,64,820.9552W Range:₹342.55₹617.45
NSE BSE www.thyrocare.com AI Report
Key Ratios
Checked 2d ago
Market Cap₹9,251 Cr
Current Price₹580
Previous Close₹579.71
High / Low (52w)₹617.45 / ₹342.55
Volume39,58,272
Avg Vol (1W)34,91,224.2
Avg Vol (1M)11,64,820.95
Stock P/E51.17
Book Value₹32.21
Dividend Yield248%
ROE27.85%
ROA23.54%
Revenue (TTM)₹846 Cr
Revenue Growth20.6%
Profit Margin20.13%
Total Debt₹0 Cr
Shares Outstanding16 Cr
Face Value₹10
EPS (TTM)₹11.36
P/B18.04
Debt / Equity0.07
50 DMA₹534.44
200 DMA₹456.14
Day change+0.05%
SurveillanceENCUMBRANCE
Price Chart
₹580▲ 37.26% · 1Y
₹580₹3502.3Cr
2025-07-29
2026-07-27

20-day avg volume: 11.6L shares

Pros
  • Healthy return on equity of 27.9%.
  • Pays a dividend yield of 248.0%.
  • Company is almost debt-free.
Cons
  • Stock trades at a high P/E of 51.
Quarterly Results
MetricSept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Revenue₹177 Cr₹166 Cr₹187 Cr₹193 Cr₹217 Cr₹196 Cr₹224 Cr₹240 Cr
EBITDA₹38 Cr₹29 Cr₹49 Cr₹51 Cr₹63 Cr₹41 Cr₹65 Cr₹69 Cr
Net Profit₹27 Cr₹19 Cr₹22 Cr₹39 Cr₹48 Cr₹29 Cr₹47 Cr₹52 Cr
EPS————————
Profit & Loss (Annual)
MetricMar 2025Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Mar 2026Jun 2026
Revenue₹702 Cr₹174 Cr₹179 Cr₹202 Cr₹182 Cr₹211 Cr₹846 Cr₹226 Cr
EBITDA₹150 Cr₹48 Cr₹52 Cr₹61 Cr₹42 Cr₹63 Cr₹220 Cr₹68 Cr
Net Profit₹92 Cr₹22 Cr₹36 Cr₹43 Cr₹26 Cr₹44 Cr₹163 Cr₹50 Cr
EPS17.08—————10.24—
Balance Sheet
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets₹475 Cr₹471 Cr₹546 Cr₹608 Cr₹633 Cr₹644 Cr₹693 Cr₹747 Cr
Total Liabilities₹40 Cr₹104 Cr₹119 Cr₹81 Cr₹98 Cr₹116 Cr₹146 Cr₹161 Cr
Equity₹435 Cr₹367 Cr₹427 Cr₹527 Cr₹535 Cr₹528 Cr₹547 Cr₹586 Cr
Total Debt————————
Cash Flow
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating₹161 Cr₹212 Cr₹158 Cr₹170 Cr₹158 Cr₹197 Cr₹233 Cr₹273 Cr
Investing₹-12 Cr₹1 Cr₹-49 Cr₹-24 Cr₹-39 Cr₹-91 Cr₹-53 Cr₹-23 Cr
Financing₹-94 Cr₹-165 Cr₹-62 Cr₹-89 Cr₹-86 Cr₹-85 Cr₹-130 Cr₹-170 Cr
Free Cash Flow₹161 Cr₹212 Cr₹158 Cr₹170 Cr₹158 Cr₹197 Cr₹233 Cr₹273 Cr
Shareholding
Promoter 60.92% Institutions 26.36% Public 12.72%
About Thyrocare Technologies Ltd.

Healthcare · Healthcare

Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates through three segments: Diagnostic Testing Services, Imaging Services, and Others. The Diagnostic Testing Services segment engages in the selling of consumables used for collection, and promotion of pathology. The Imaging Services segment sells radio-pharmaceutical and consumables for reporting. The Others segment engages in the sale of testing equipment and consumables; and glucometer and glucostrips under the brand name sugarscan. The company offers diagnostic and pathological services. The company was founded in 1996 and is based in Navi Mumbai, India. Thyrocare Technologies Limited is a subsidiary of Docon Technologies Private Limited.

www.thyrocare.com ↗
Efficiency & Working Capital
ROCE33.9%
Interest Coverage54.8
Dividend Payout—
Debtor Days33 d
Inventory Days21 d
Payable Days29 d
Cash Conversion Cycle25 d
Working Capital Days54 d
Shareholding Details

As of 2026-06-30

Promoter60.9%
FII5.4%
DII20.9%
Institutions26.4%
Public12.7%
Promoter Pledge100%
No. of Shareholders73,064
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Promoters71.1%71.1%71.1%71.1%71.1%71.1%71.1%71.1%71.1%60.9%60.9%60.9%
FIIs3.5%3.3%2.9%2.5%1.9%2.8%2.4%3.2%4.8%5%5.4%5.4%
DIIs13.3%13.6%14.9%14.9%14.8%14.7%15%14.5%13.5%20.5%21%20.9%
Public12.1%12%11.1%11.5%12.2%11.5%11.6%11.2%10.6%13.6%12.7%12.7%
Promoter Pledge100%100%100%100%100%100%100%100%85.8%100%100%100%
No. of Shareholders72,00068,84464,82361,63659,37756,66657,40354,56654,14277,61973,37773,064
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202603————
Major Shareholders (>1%)
NameCategoryStakeShares
Docon Technologies Private LimitedShareholding of Promoter and Promoter Group60.9%9.70 Cr
Nippon Life India Trustee Ltd-a/c Nippon India Small Cap FundPublic Shareholding6%95,34,712
Icici Prudential Pharma Healthcare And Diaganostics (p.h.d) FundPublic Shareholding5.6%88,57,893
Hsbc Mutual Fund - Hsbc Midcap FundPublic Shareholding3.8%61,10,670
Aditya Birla Sun Life Trustee Private Limited A/c - Aditya Birla Sun Life Elss Tax Saver FundPublic Shareholding3.2%50,07,086
Api Holdings LimitedShareholding of Promoter and Promoter Group0%0
Promoter Pledges
HolderPledged Shares% of HoldingAs of
Docon Technologies Private Limited9.70 Cr100%2026-06-30
Board of Directors
NameDesignationYear
Rahul Franklin GuhaChairman / Executive Director / MD / CEO2026
Alok Kumar JagnaniNon Independent Non Executive Director / CFO2026
Uday Patel KadamNon-Exec & Non-Independent Dir2026
Gaurav VermaNon-Exec & Non-Independent Dir2026
Indumati GopinathanIndependent Non Exe. Director2026
Prapti Ishwar GiladaIndependent Non Exe. Director2026
Harshil Jiten VoraIndependent Non Exe. Director2026
Nishant A. ShahIndependent Non Exe. Director2026
Anandh SundarIndependent Non Exe. Director2026
Brijesh KumarCompany Sec. & Compli. Officer2026
Segments — Product
SegmentRevenueShare
Diagnostic services₹0 Cr—
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2026₹10300159159
Corporate Actions
TypeDateValueRemark
forthcoming2026-07-23Board Meetings—
dividend2026-06-23₹7.0 (70.0%)Final
dividend2026-06-23₹7 (70%)Final
bonus2025-11-282:12:1 Bonus Issue of Equity Shares
dividend2025-10-24₹7 (70%)Interim
dividend2025-07-25₹21 (210%)Final
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
2026110080247
20268000025
202610080120
Insider / Designated-Person Trades

55 recent disclosure(s)

Nikhil BodhankarDisposal · 90
Nikhil BodhankarDisposal · 90
Nikhil BodhankarDisposal · 200
Nikhil BodhankarDisposal · 90
Nikhil BodhankarDisposal · 200
Sarovar ChandraAcquisition · 450
Substantial Acquisitions (SAST)

2 disclosure(s)

Market24/10/2025 · 53,32,860
Market24/10/2025 · 19,98,400
Company Information
Incorporated2000
ChairmanRahul Franklin Guha
AuditorMSKA & Associates
Investor Email[email protected]; [email protected]
🌐 www.thyrocare.com ↗

📍 D-37/1 TTC Industrial Area, MIDC Turbhe, Navi Mumbai, Maharashtra, 400703

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

Log inSign up free

More stocks

Leela Palaces Hotels & Resorts Ltd.Themis Medicare Ltd.Thermax Ltd.Thinking Hats Entertainment Solutions Ltd.Thomas Cook (India) Ltd.Thomas Scott (India) Ltd.Tilaknagar Industries Ltd.Twamev Construction & Infrastructure Ltd.Tiger Logistics (India) LimitedTechnocraft Industries (India) Ltd.Tube Investments of India Ltd.Tijaria Polypipes Ltd.All “T” stocks →

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search